Cytoki's IL-22 Analogue Promising for Obesity and Diabetes

1 August 2024
Cytoki Pharma shared encouraging early data for its experimental drug CK-0045, a lipidated IL-22 analogue, from a Phase I study involving 76 healthy participants and those with obesity. This drug demonstrated favorable outcomes on important cardiometabolic parameters, indicating potential for treating obesity and type 2 diabetes either alone or in combination with other treatments. Rasmus Jørgensen, the CEO of Cytoki, expressed optimism about CK-0045’s prospects, noting the data's adequacy to support its progression into mid-stage trials slated for the latter half of the year.

CK-0045 is an analogue of the non-immunomodulatory cytokine IL-22, designed to selectively target epithelial cells in the gut and liver. The biotech company underscores the drug’s unique mechanism of action, which mimics the natural effects of IL-22 and could be beneficial in addressing various metabolic and inflammatory conditions. Previous preclinical studies in mice demonstrated significant weight loss and enhanced glucose regulation.

The Phase I study confirmed that CK-0045 effectively engaged its targets, as evidenced by liver and gut biomarkers. Pharmacokinetic data supported the practicality of once-weekly subcutaneous dosing. Additionally, reductions in body mass and improvements in low-density lipoprotein cholesterol, insulin levels, and insulin resistance were recorded, particularly in participants with diminished insulin sensitivity. The safety profile was favorable, with the drug being well-tolerated and no major gastrointestinal side effects observed.

Cytoki Pharma was established in 2019 by Rasmus Jørgensen, who previously led research at Novo Nordisk. CK-0045, licensed from Novo, is positioned as the company’s primary focus.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!